Endoscopic retrograde cholangiopancreatography (ERCP)
Conditions
Interventions
Observion group:Using the modified Dixon sequential trial method, the initial dose of oxaliplatin in the first patient was 20ug/kg, with a ratio of adjacent drug doses of 1.0:1.2. When the patient exp
Sponsors
Tianjin Nankai Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 84 Years
Inclusion criteria
Inclusion criteria: 1. Age 18-84 years old, with no restrictions on gender or ethnicity. 2. Body mass index (BMI) ranging from 18 to 30 kg/m², and American Society of Anesthesiologists (ASA) physical status classification of grade I - III. 3. Patients scheduled to undergo elective endoscopic retrograde cholangiopancreatography (ERCP) under anesthesia while maintaining spontaneous respiration. 4. Agree to participate in this study and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Those who have chronic pain and have been taking analgesics, psychotropic drugs for a long time, or are alcohol abusers; 2. Those with severe preoperative renal function abnormalities; 3. Those with a history of abnormal recovery from surgical anesthesia in the past; 4. Those suffering from esophageal reflux disease; 5. Those who have used sedatives, analgesics or antipruritic drugs within 24 hours before the operation; 6. Patients expected to have airway difficulties; 7. Those who have undergone liver surgeries; 8. Those with a history of opioid allergy; 9. Those who have taken monoamine oxidase inhibitor drugs or antidepressant drugs within fifteen days; 10. Those with a definite diagnosis of heart diseases (such as heart failure, angina pectoris, myocardial infarction, arrhythmia, etc.), lung diseases (such as asthma, chronic obstructive pulmonary disease (COPD), pulmonary embolism, pulmonary edema or lung cancer), or central nervous system abnormalities; 11. Epileptic patients; 12. Pregnant women or women during lactation; 13. Those who have participated in other clinical studies within 3 months before enrollment; 14. Those who are unable to communicate normally.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Successful placement of duodenoscopy or not;ED50;ED90; | — |
Secondary
| Measure | Time frame |
|---|---|
| The number of occurrences ofhypoxemia;Hemodynamics;MOAA/S score;BIS;nausea and vomiting;somnolence;itch;dizziness;headache;delirium;restlessness;Injection pain;hiccup;The incidence rate of paroxysmal cough; | — |
Countries
China
Contacts
Public ContactJianbo Yu
Tianjin Nankai Hospital
Outcome results
None listed